|
 
 |
| EDITORS PAGE |
|
| Year : 2017 | Volume
: 6
| Issue : 1 | Page : 1 |
|
From the Editor's desk
Ravi R Kasliwal MD, DM
Editor-in-chief, Journal of Clinical and Preventive Cardiology, India
| Date of Web Publication | 26-Dec-2016 |
Correspondence Address:
Dr. Ravi R Kasliwal
Chairman, Clinical and Preventive Cardiology, Medanta - The Medicity, Sector 38, Gurgaon, Haryana - 122 001
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2250-3528.196646
How to cite this article:
Kasliwal RR. From the Editor's desk
. J Clin Prev Cardiol 2017;6:1 |
January 2017, the dawn of another New Year! As radical transformation is taking place in the Indian society, life styles are getting diverse, cultural values are shifting, non-communicable diseases are increasing and truly, the winds of change are blowing in the country, welcome to a New Year and gear up for challenges and ecstasy and exciting science and daunting problems, solutions and engagement. Team JCPC wishes you a thought provoking New Year!
Women's cardiovascular health has always been neglected because most of them are homemakers and not bread earners, even though ASCVD continues to be their 'numero uno' killer. The two contributions in the present issue are thought provoking and set the tone for more women-centric preventive articles to follow. Stay tuned.
Two new therapies are also discussed- an old, established one and another new and promising, but the latter still has miles to go before it truly becomes well established and comes into everyday use.
The PCSK9 inhibitors are monoclonal antibodies. These can be called "designer drugs" because they specifically fight the ill-effects of a molecule called 'proprotein convertase subtilisin kexin 9', thus reducing LDL cholesterol to really low levels in the blood stream. Early evidence suggests that profound LDL cholesterol reduction with these drugs may reduce the risk of ASCVD dramatically, possibly much more than what we have ever witnessed. The first two PCSK9 inhibitors- Alirocumab and Evolocumab- are already approved by the United States Food and Drug Administration (2015) for difficult to treat elevations of LDL cholesterol. This is one of the reasons, I believe, these are exciting times for cardiovascular physicians engaged in secondary prevention of ASCVD.
Cilnidipine, on the other hand, is a known antihypertensive agent and has been in the clinical arena for quite some time. It is a dihydropyridine calcium antagonist which blocks both N-type and L-type calcium channels and hence dilates both arteries and venules and reduces blood volume in the capillary bed. It is an effective antihypertensive agent for mild- to moderately-high blood pressure and causes less peripheral edema than amlodipine.
The San Francisco Syncope Rule (SFSR) is a simple tool for risk stratification in patients presenting with syncope. One of the original articles included in this issue explores applicability of this tool in Indian subjects, a definite clinical need.
Pulmonary embolism and pulmonary hypertension are clinical entities that need more study, more application and more understanding in the emergency room. The landmark trials reviewed in this issue just do that.
So, dear Reader, 2016 is history, 2017 beckons. Best Wishes for a very Happy New Year!
|
Search Pubmed for